BioMarin Pharmaceutical (BMRN, Financial) , which develops pharmaceuticals for rare, often genetic, diseases, fell after an unexpected U.S. Food and Drug Administration (FDA) determination delayed the approval timeline for the company's hemophilia gene therapy, which we considered a key, near-term growth driver.
From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund third-quarter 2020 commentary.
